干细胞治疗

我们在医学领域学术上之光辉历史

1987 treatment of patients with cytostatic myelodepression and aplastic anemia (filing of patent application).治疗骨髓细胞抑郁症及再生不良贫血。

1991 clinical trials and invention of acquired immune deficiency syndrome (AIDS) and HIV-infection treatment method; filing of patent application in the USA (priority since 1993).治疗爱滋病;赢得美国专利。

1992 successful application of fetal stem cells (in vivo) in clinical trials for treatment of type 1 and 2 diabetes mellitus, filing of patent application.
治疗糖尿病I,II型。

1993...1994 foundation of the Cell Therapy Clinic of the NationalMedicalUniversity (17 Solomenskaya Str., Kiev, Ukraine). Clinical trials of cell transplants for treatment of different diseases and conditions.
First Ukrainian patents granted. The beginning of development of multiple sclerosis treatment methods.治疗多发性硬化症。

1995 application of fetal stem cells (in vivo) for treatment of amyotrophic lateral sclerosis. First efforts to apply different types of cell suspensions for treatment of muscular dystrophies, in particular Duchenne Muscular Dystrophy.治疗杜金氏营养不良症与侧边肌肉萎缩硬化症。

1998...2001 Greek, USA, Russian Federation and Ukrainian patents granted.获得希腊,美国与苏联之专利。

1999 Ministry of Healthcare of Ukraine approval of methodological recommendations on application of fetal stem cells in oncology, developed by the clinic.得到卫生部的准许,利用干细胞运用于癌症病患。

2000 Ministry of Healthcare of Ukraine approval of methodological recommendations on application of fetal stem cells in diabetes treatment, developed by the clinic.卫生部批准运用于临床糖尿病患者。

2001 Ministry of Healthcare of Ukraine approval of methodological recommendations on application of fetal stem cells in hematology, developed by the clinic.乌克兰卫生部批准胚胎干细胞运用于血液科疾病。


2002 “Most Innovative Work” Award granted by the Scientific Committee of the Annual Meeting of the Society of Medical Innovations and Technology (SMIT) held in Oslo, Norway. The first Dutch patent granted. Ministry of Healthcare of Ukraine approval of methodological recommendations on application of fetal stem cells in endocrinology, developed by the clinic.
受医学会之委员奖赏为“最革新的医药突破”。在挪威Oslo革新技术学会(SM IT)给予第一次专利。乌克兰卫生部也批准干细胞运用于内分泌之疾病。

2003 The second Dutch patent granted.荷兰给予第二个专利。

2004 Ukrainian and Russian Federation patents granted. Development and patenting of methods of intestine diseases treatment (Crohn’s disease, non-specific ulcerative colitis, etc.). Working out of ethical norms on the work with human fetal cells approved by the Ministry of Healthcare of 7 Ukraine.
获得乌克兰与苏联专利。乌克兰卫生部批准运用在肠胃之毛病如溃疡性大肠炎,格氏病症。

2005...2007 extension of active clinical and scientific activities, participation in the numerous conferences and congresses, direct participation in the work of international societies and associations, such as Cellular Therapy Society, Cell Transplant Society, Multinational Association of Supportive Care in Cancer, Society for Minimally Invasive Therapy, EASD.参与无数的临床医学活动及国际研讨会。

2008 development of methods of fetal cell suspensions application in surgical practice, in particular for treatment of erosive-ulcerative lesions of stomach and duodenum complicated by bleeding. Elaboration of patient surveillance that was declared the best at the 1-st Central European Congress on Surgery (Prague, Czech Republic).
研发干细胞悬浮液治疗外科疾病,胃及十二指肠溃疡。並在欧洲发表。

2009 Ukrainian patents granted.获得乌克兰专利。

2010 Beginning of different cell suspensions application for treatment of thermal injuries of various complexity and localization.开始利用不同种类的干细胞来治疗无数复杂及各部位之烧伤病患。


Biotechnology of stem cell isolation and storage
利用生物科技,分离及储存胚胎干细胞


UCTC利用现代最维新的方法来分离,生产及储存胚胎干细胞。我们自己利用医学科技制成胚胎干细胞之悬浮液,且经过测试验证才运用于临床及科学领域的研究上。

干细胞悬浮液的制作,是经过精心的配制,混合多种不同的胚层之干细胞而制成再移植给病患。这种完美无缺高品质的配方使到我们更有信心会给予病人达到理想的治疗效果。

胚胎干细胞悬浮液之医药制造过程是依据生物科技的步骤阶段进行:

1.)胚胎干细胞的来源是符合法律及人道上的需求,帅选最优良的材料,配合适当的时宜,在特别专门的医药部门进行配制。

2.)所制成的胚胎干细胞悬浮液将会储存在无菌的容器内。

3.)悬浮液未冷冻储存前,先得测试他们的安全性及活动性。

4.)冷冻储存之悬浮液在未作移植前一定先要有同样的计划。

5.)在未给予病人移植前,先解冻,测试他们的安全性及存活力。
6.)胚胎干细胞悬浮液可长期保存在冷冻库中(Cryobank)。

Cell Suspension Bank
冷冻储存库

UCTC有先进及高科技的细胞冷冻储存库。他包括现代的Dewar flasks and cryogenic banks (tanks) 冷冻库,可储存大量(10千以上)的胚胎干细胞悬浮液。